Finoriq research workspace
Avalo Therapeutics, Inc. (AVTX) News
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for. Review AVTX recent headlines, source links, and company news on Finoriq.
Company Snapshot
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
- Company
- Avalo Therapeutics, Inc. (AVTX)
- Ticker
- AVTX
- Market Cap
- $967.7M
- Latest Price
- $18.41
- Industry
- Biotech & Pharma
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.